INTRODUCTION AND OBJECTIVES:
The APOBEC family of enzymes is responsible for a mutation signature characterized by a TcW->T/G mutation. APOBEC-mediated mutagenesis is implicated in a wide variety of tumors, including bladder cancer. However, less is known about regulation and function of the APOBEC genes and their subsequent mutation signature. In this study, we explore the APOBEC mutational signature in bladder cancer and the relationship with mutation burden, molecular classification, gene expression, and survival.
METHODS: The Cancer Genome Atlas (TCGA) bladder urothelial carcinoma data was downloaded from cBioPortal (http://cbioportal.org) and the Broad Institute (http://gdac.broadinstitute.org). APOBEC enrichment score was calculated as previously described (Nat Genet 2013; 45:970) . Tumors with >2-fold enrichment with a Benjamini-Hochberg corrected p-value <0.05 were considered high in APOBEC enrichment. Statistical analysis was performed with R. Functional annotations were performed with DAVID (http:// david.ncifcrf.gov).
RESULTS: Expression of APOBEC3A and APOBEC3B are associated with the mutational burden in bladder cancer (r¼0.18, p<0.001; r¼0.334, p<0.001). High APOBEC enrichment score is associated with improved overall survival ( Figure 1A ). APOBEC enrichment does not vary between TCGA molecular subtypes 1-4 ( Figure 1B ). Of the top mutated genes in bladder cancer, patients with high APOBEC enrichment are more likely to have mutations in TP53, ERBB2, KMT2C and PIK3CA, but not ARID1A, CSMD3, RB1, KMT2D, KDM6A, or STAG2. Genes with expression positively associated with APOBEC enrichment (including PD-1, CTLA-4, TIM-3, and TIGIT) are involved in IFN-gamma signaling, antigen processing and presentation, and regulation of the immune response, while genes negatively associated with APOBEC enrichment are involved in translational initiation and ribosome assembly.
CONCLUSIONS: APOBEC enzymes are a major source of mutation in bladder cancer. Both luminal and basal subtypes of bladder cancer have similar APOBEC mutational signatures. This signature is associated with overall survival as well as expression of immune-related genes. Further study of regulation of APOBEC enzymes may provide further insight into the mutational landscape and potential therapeutics for bladder cancer. INTRODUCTION AND OBJECTIVES: Genomic tracking from liquid biopsy such as urine and blood is a novel technique with the potential to monitor presence of tumour material non-invasively. To identify truncal mutations within heterogeneous tumours, an individualised or large panel multi-target approach must be used to monitor response. The complete response rate to chemotherapy for metastatic bladder cancer (BC) is limited, but the ability to identify response could be of significance in the neo-adjuvant setting. The aim of this study is to test the feasibility of detecting and monitoring somatic mutations in cell-free DNA (cfDNA) found in plasma of patients with BC pre and post-treatment.
METHODS: 25 patients with muscle-invasive BC and 10 patients with metastatic BC were selected for this study. Patients with metastatic BC received at least 2 cycles of gemcitabine and cisplatin chemotherapy. 10 ml of blood was collected in EDTA tubes at each timepoint. Samples were taken at baseline for all patients, twelve weeks after surgery for the cystectomy cohort, and before each cycle of chemotherapy for the metastatic cohort. Plasma was separated by centrifugation, and cfDNA extracted with the QIAamp Circulating Nucleic Acid Kit. Targeted amplification was performed using duel indexed primers, followed by next generation sequencing (NGS) using a panel of known (TERT PIKC3, FGFR3, HRSA) and novel BC mutations. Changes in cfDNA mutation burden were compared with cross sectional imaging, and response was assessed using the RECIST criteria.
RESULTS: cfDNA was isolated from all samples at baseline and subsequent treatment. Baseline DNA quantification was performed, and a mean of 77.5 and IQR 10.9-72.7 ng/ml (Qubit) collected. This did not correlate with baseline disease burden or subsequent response to chemotherapy. Mutation profiles varied between patients, but at least one mutation was identified the plasma cfDNA of all patients. Dynamic changes in the mutational burden were detected in several patients. In a few patients with nodal disease, mutational changes were still detectable post-cystectomy.
CONCLUSIONS: Plasma cfDNA is detectable in patients with BC but its quantity is not a reliable indicator of disease burden. Mutational analysis of plasma cfDNA is feasible for use as a non-invasive biomarker of therapeutic response to chemotherapy, and the presence of residual disease post-cystectomy. Dynamic changes in mutational burden for each patient are likely to be related to their individual tumour's heterogeneity, and the expansion of sub-clonal populations in both primary and metastatic lesions.
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MP44-14 DOWNREGULATION OF MIR-200B IS ASSOCIATED WITH CISPLATIN-RESISTANCE IN BLADDER CANCER CELLS
Tetsuya Shindo*, Naotaka Nishiyama, Takeshi Niinuma, Hiroshi Kitajima, Masahiro Kai, Takashi Tokino, Nobuo Shinkai, Hiromu Suzuki, Naoya Masumori, Sapporo, Japan INTRODUCTION AND OBJECTIVES: Chemoresistance to cisplatin (CDDP) is one of the major clinical issues in bladder cancer (BCa) treatment. MicroRNAs (miRNA) are noncoding RNAs that are potentially involved in chemoresistance in various cancers. We therefore aimed to determine the roles of miRNAs in the CDDP-resistance in BCa.
METHODS: We established 2 CDDP-resistant BCa cell lines (T24RC and EJ138RC) by continuously treating parental T24 and EJ138 cells. Profiles of miRNA expression in BCa cells were assessed by TaqMan arrays (Applied Biosystems). BCa cells were transfected with a mimic or an inhibitor of miR-200b (Ambion), after which the sensitivities to CDDP were evaluated via cell viability assays.
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